SCHEMBL2740949

SCHEMBL2740949

O=[N+]([O-])c1ccc(N/N=C/c2ccccc2-c2cccnc2)c(S(=O)(=O)Nc2ccccc2Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 11/20 0.54
▸ KMT2A Q03164 11/20 0.54
▸ HTT P42858 6/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ NPC1 O15118 5/20 0.54
▸ PSMD14 O00487 2/20 0.54
▸ MAPT P10636 13/20 0.50
▸ GAA P10253 7/20 0.50
▸ PLA2G1B P04054 1/20 0.50
▸ ATG4B Q9Y4P1 1/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ GLA P06280 2/20 0.48
▸ TLR9 Q9NR96 1/20 0.48
▸ TNNI3 P19429 1/20 0.44
▸ TNNT2 P45379 1/20 0.44
▸ TNNC1 P63316 1/20 0.44
▸ ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741013 0.91 MEN1 (0.58) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740985 0.86 MEN1 (0.54) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740986 0.82 MEN1 (0.56) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740992 0.81 MEN1 (0.49) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740951 0.79 MEN1 (0.57) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740987 0.79 MEN1 (0.55) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740993 0.79 MAPT (0.55) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2740990 0.78 L3MBTL1 (0.57) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2741006 0.78 MEN1 (0.55) MEN1KMT2AHTTRAB9ASMN1; SMN2
SCHEMBL2741007 0.77 MEN1 (0.58) MEN1KMT2AHTTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
EP-1932830-A1 Sulfonamides and their use as a medicament The Genetics Company, Inc. (CH) 2008-06-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 MEN1 1381/4885KMT2A 217/4885HTT 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback